Payment overview · 2025
General Payments
$360.88
8 reported records · 6 companies
Healthcare provider profile · identity verified
Haley Laura Mock, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GASTONIA, NC · NPI 1750076238
Verified facts
What the public records show
CMS Open Payments records show Haley Laura Mock, NP received $360.88 in general payments during 2025 across 8 reported records.
Janssen Biotech, Inc. accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $131.18 | 36.4% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $125.96 | 34.9% | 2 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $34.12 | 9.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.06 | 7.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $24.01 | 6.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.55 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.88 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $125.96 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $112.24 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $34.12 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 66 |
| Lisinopril | Lisinopril | 198 | 54 |
| Metformin Hcl | Metformin Hcl | 143 | 44 |
| Gabapentin | Gabapentin | 135 | 37 |
| Omeprazole | Omeprazole | 128 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 37 |
| Losartan Potassium | Losartan Potassium | 119 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 108 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 35 |
| Trazodone Hcl | Trazodone Hcl | 92 | 31 |
| Simvastatin | Simvastatin | 91 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 26 |
| Clonazepam | Clonazepam | 86 | 21 |
| Meloxicam | Meloxicam | 83 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 31 |
| Metformin Hcl Er | Metformin Hcl | 76 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 23 |
| Alendronate Sodium | Alendronate Sodium | 68 | 17 |
| Eliquis | Apixaban | 68 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 18 |
| Jardiance | Empagliflozin | 65 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 14 |
| Carvedilol | Carvedilol | 61 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 17 |
| Montelukast Sodium | Montelukast Sodium | 53 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 18 |
| Allopurinol | Allopurinol | 52 | 13 |
| Furosemide | Furosemide | 51 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 16 |
| Potassium Chloride | Potassium Chloride | 48 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 18 |
| Tramadol Hcl | Tramadol Hcl | 44 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 18 |
| Bupropion Xl | Bupropion Hcl | 41 | 12 |
| Methylprednisolone | Methylprednisolone | 38 | 38 |
| Famotidine | Famotidine | 37 | 15 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | 12 |
| Buspirone Hcl | Buspirone Hcl | 32 | 13 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | 12 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 11 |
| Prednisone | Prednisone | 12 | 12 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.88 · 8 records | Janssen Biotech, Inc. | ELIQUIS, ERLEADA, JEMPERLI, RYBREVANT, Tecentriq, Vonjo, ZEJULA, clonoSEQ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error